FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2362732329> ?p ?o ?g. }

• W2362732329 abstract "Objective To observe the efficacy and safety of the recombinant human tissue type plasminogen kinase derivative( rPA) combined with creatine phosphate sodium in the treatment of acute ST segment elevation myocardial infarction. Methods A total of 70 acute ST segment elevation myocardial infarction patients in compliance with thrombolytic therapy indications were randomly divided into conventional thrombolytic therapy group and creatine phosphate sodium group,35 cases in each group. The creatine phosphate sodium was used while the thrombolytic therapy was given in the creatine phosphate group. The activity of plasma cardiac troponin I( cTnI),creatine kinase isoenzyme( CK-MB) and superoxide dismutase( SOD) were detected in two groups before and 24 hours after treatment respectively. Echocardiography was examined in all patients by 2 weeks. Left ventricular end diastolic diameter,left ventricular end systolic diameter and left ventricular ejection fraction were determined and calculated by Simpson method. The occurrence of cardiovascular adverse event within 2 weeks in the 2 groups was observed. Results The recanalization rate in creatine phosphate sodium group was higher than that in routine therapy group( 65. 7% vs 62. 8%),with no significant differences between the two groups( P 0. 05). The plasma levels of CK-MB,cTnI and SOD were higher than that before treatment,the plasma level increase of SOD was lower than that of CK-MB and cTnI( P 0. 05). The increased degree of plasma CK-MB and cTnI in creatine phosphate sodium group were significantly lower than that of the routine therapy group,the activity of SOD was significantly higher than that of the routine therapy group( P 0. 05). The left ventricular end diastolic diameter and left ventricular end systolic diameter in the routine therapy group were higher than those of the creatine phosphate sodium group, left ventricular ejection fraction was lower than that of the creatine phosphate sodium group. The incidence of infarction angina,myocardial reinfarction and malignant arrhythmia in the creatine phosphate sodium group were significantly decreased than those of the routine thrombolytic therapy group( P 0. 05); there were no significant differences between the two groups on the incidence of ardiogenic shock,mortality and bleeding( P 0. 05). Conclusion Creatine phosphate sodium has protective effect on myocardial ischemia/reperfusion injury in myocardial infarction; rPA combined with creatine phosphate sodium could reduce the occurrence of short-term complications after coronary artery recanalization in the treatment of acute ST segment elevation myocardial infarction." @default.
• W2362732329 created "2016-06-24" @default.
• W2362732329 creator A5075041232 @default.
• W2362732329 date "2014-01-01" @default.
• W2362732329 modified "2023-09-25" @default.
• W2362732329 title "Short-term Clinical Effect about rPA Combined with Creatine Phosphate Sodium in the Treatment of Acute ST Segment Elevation Myocardial Infarction" @default.
• W2362732329 hasPublicationYear "2014" @default.
• W2362732329 type Work @default.
• W2362732329 sameAs 2362732329 @default.
• W2362732329 citedByCount "0" @default.
• W2362732329 crossrefType "journal-article" @default.
• W2362732329 hasAuthorship W2362732329A5075041232 @default.
• W2362732329 hasConcept C115725540 @default.
• W2362732329 hasConcept C126322002 @default.
• W2362732329 hasConcept C164705383 @default.
• W2362732329 hasConcept C2778198053 @default.
• W2362732329 hasConcept C2779896295 @default.
• W2362732329 hasConcept C36036425 @default.
• W2362732329 hasConcept C36880943 @default.
• W2362732329 hasConcept C500558357 @default.
• W2362732329 hasConcept C71924100 @default.
• W2362732329 hasConcept C78085059 @default.
• W2362732329 hasConceptScore W2362732329C115725540 @default.
• W2362732329 hasConceptScore W2362732329C126322002 @default.
• W2362732329 hasConceptScore W2362732329C164705383 @default.
• W2362732329 hasConceptScore W2362732329C2778198053 @default.
• W2362732329 hasConceptScore W2362732329C2779896295 @default.
• W2362732329 hasConceptScore W2362732329C36036425 @default.
• W2362732329 hasConceptScore W2362732329C36880943 @default.
• W2362732329 hasConceptScore W2362732329C500558357 @default.
• W2362732329 hasConceptScore W2362732329C71924100 @default.
• W2362732329 hasConceptScore W2362732329C78085059 @default.
• W2362732329 hasLocation W23627323291 @default.
• W2362732329 hasOpenAccess W2362732329 @default.
• W2362732329 hasPrimaryLocation W23627323291 @default.
• W2362732329 hasRelatedWork W2002102389 @default.
• W2362732329 hasRelatedWork W2020807472 @default.
• W2362732329 hasRelatedWork W2031382315 @default.
• W2362732329 hasRelatedWork W2037634668 @default.
• W2362732329 hasRelatedWork W2066186908 @default.
• W2362732329 hasRelatedWork W2172144824 @default.
• W2362732329 hasRelatedWork W2245834348 @default.
• W2362732329 hasRelatedWork W2356818143 @default.
• W2362732329 hasRelatedWork W2362954103 @default.
• W2362732329 hasRelatedWork W2364689633 @default.
• W2362732329 hasRelatedWork W2369371137 @default.
• W2362732329 hasRelatedWork W2373197030 @default.
• W2362732329 hasRelatedWork W2375599537 @default.
• W2362732329 hasRelatedWork W2378299590 @default.
• W2362732329 hasRelatedWork W2381397400 @default.
• W2362732329 hasRelatedWork W2406897031 @default.
• W2362732329 hasRelatedWork W2416036425 @default.
• W2362732329 hasRelatedWork W3029514344 @default.
• W2362732329 hasRelatedWork W3029842917 @default.
• W2362732329 hasRelatedWork W3196774031 @default.
• W2362732329 isParatext "false" @default.
• W2362732329 isRetracted "false" @default.
• W2362732329 magId "2362732329" @default.
• W2362732329 workType "article" @default.